Complement C1 esterase inhibitor and Insulin glargine and lixisenatide Subcutaneous
Determining the interaction of Complement C1 esterase inhibitor and Insulin glargine and lixisenatide Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: C1 esterase inhibitor (human)
Brand name: Berinert, Cinryze, Haegarda, Ruconest
Synonyms: C1 Inhibitor (Human)
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Complement C1 esterase inhibitor-Insulin glargine, recombinant Subcutaneous
- Complement C1 esterase inhibitor-Insulin glulisine
- Complement C1 esterase inhibitor-Insulin Glulisine (Cartridges and Pens)
- Complement C1 esterase inhibitor-Insulin Glulisine (Vials)
- Complement C1 esterase inhibitor-Insulin glulisine Subcutaneous
- Complement C1 esterase inhibitor-Insulin human inhaled Inhalation
- Insulin glargine and lixisenatide Subcutaneous-Complera
- Insulin glargine and lixisenatide Subcutaneous-Complete Allergy
- Insulin glargine and lixisenatide Subcutaneous-Complete-RF Prenatal
- Insulin glargine and lixisenatide Subcutaneous-Complex A Tretinoin Cream
- Insulin glargine and lixisenatide Subcutaneous-Compliments Bismuth - Regular Strength
- Insulin glargine and lixisenatide Subcutaneous-Compound W